Key facts
- It has raised $3.8M across 1 recorded rounds; the latest was Seed Round ($2.3M) in Jan 2022.
- Notable investors include Y Combinator, Pioneer Fund, Gaingels, Metaplanet Holdings, Harvard Innovation Launch Lab — 16 tracked in total.
- Promakhos Therapeutics has filed 1 Form D with the SEC, most recently Jan 2022 ($2.2M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Promakhos Therapeutics
Funding rounds
1 roundsAbout Promakhos Therapeutics
Developer of immunotherapies designed for the treatment of inflammatory diseases. The company has developed modulators of innate immune receptors to restore the immune system's balance and function, control inflammation, and heal without relying on immune suppression, enabling doctors to treat chronic inflammatory disorders.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2021
- Employees
- 4
- Website
- promakhos.com/
- Ownership
- Privately Held (backing)
Promakhos Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Promakhos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Promakhos Therapeutics in its N-PORT filings yet. We sweep new filings monthly.